In a report released today, Matthew Luchini from BMO Capital maintained a Buy rating on NGM Biopharmaceuticals (NGM), with a price target of $38.00. The company’s shares closed last Friday at $27.05.
According to TipRanks.com, Luchini is a 3-star analyst with an average return of 6.8% and a 40.2% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Applied Genetic Technologies, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NGM Biopharmaceuticals with a $42.83 average price target, implying a 59.9% upside from current levels. In a report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $43.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.12 and a one-year low of $14.93. Currently, NGM Biopharmaceuticals has an average volume of 206.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.